#Coronavirus #コロナウイルス Vol.12 / Science and Technology 科学技術 Vol.10(Pharmaceutical products 医薬品 Vol.3:Vaccines ワクチン)

All the below links and excerpts are in English.

標記関連リンクと当方作成の一部抜粋を取り急ぎ以下のとおり貼っておきます。
(The below Vaccine Tracker is from @nytimes.)

Coronavirus_Vaccine-Tracker-nytimes
Coronavirus Vaccine Tracker (10/24/2020) | @nytimes
〇 Genetic Vaccines – Vaccines that deliver…coronavirus’s own genes into our cells to provoke an immune response.
• Moderna & National Institutes of Health [PHASE 3] mRNA
…planned to wait until a significant number of volunteers became sick with Covid-19 and then see how many had been vaccinated. It may take till the end of 2020 or early 2021 to reach the necessary numbers.
• BioNTech & Pfizer & Fosun Pharma (China) [PHASE 2 & 3] mRNA
… Pfizer and BioNTech would not apply for an emergency use authorization before late November at the earliest. …
…will have to be chilled to minus 80 degrees Celsius (minus 112 degrees Fahrenheit) until it’s ready to be injected.
• Zydus Cadila (India) [PHASE 2] DNA-based
• CureVac (Germany) [PHASE 2] mRNA
• Imperial College London (UK) & Morningside Ventures (UK) [PHASE 1 & 2] “self-amplifying” RNA
• AnGes (Japan) & Osaka University (Japan) & Takara Bio (Japan) [PHASE 1 & 2] DNA-based
• Arcturus Therapeutics (CA) & Duke-NUS Medical School (Singapore) [PHASE 1 & 2] mRNA
• Inovio (PA) [PHASE 1] DNA-based
• Genexine (South Korea) [PHASE 1] DNA-based
• Academy of Military Medical Sciences (China) & Suzhou Abogen Biosciences (China) & Walvax Biotechnology (China) [PHASE 1] mRNA-based
• Chulalongkorn University (Thailand) & Chula Vaccine Research Center (Thailand) [PHASE 1] mRNA-based
• Entos Pharmaceuticals (Canada) [PHASE 1] DNA
• Sanofi (France) & Translate Bio (MA) [PRECLINICAL] mRNA

〇 Viral Vector Vaccines – Vaccines that contain viruses engineered to carry coronavirus genes. …
• CanSino Biologics (China) & Academy of Military Medical Sciences (China) [PHASE 3]
• Gamaleya Research Institute (Russia) [PHASE 3]
• Johnson&Johnson & Beth Israel Deaconess Medical Center (MA) [PHASE 3]
• AstraZeneca & University of Oxford [PHASE 2 & 3]
ReiThera (Italy) & Lazzaro Spallanzani National Institute for Infectious Diseases (Italy);Vaxart (CA);Merck & Themis Bioscience (Austria) & Institut Pasteur (France);German Center for Infection Research (Germany);Merck & IAVI (NY);ImmunityBio (CA);Novartis …
〇 Protein-Based Vaccines – Vaccines that contain coronavirus proteins but no genetic material. …
• Novavax [PHASE 3]
• Anhui Zhifei Longcom (China) & Chinese Academy of Medical Sciences (China) [PHASE 2]
Finlay Vaccine Institute (Cuba);Vector Institute (Russia);Sanofi & GSK、SpyBiotech (UK);Clover Biopharmaceuticals (China) & GSK & Dynavax (CA); University of Queensland (Australia) & CSL (Australia);Medicago (Canada) & GSK & Dynavax;Vaxine (Australia);Kentucky BioProcessing (KY);Medigen (Taiwan) & Dynavax;Adimmune (Taiwan);COVAXX (NY) …
〇 Inactivated or Attenuated Coronavirus Vaccines – Vaccines created from weakened coronaviruses…
• Wuhan Institute of Biological Products (China) [PHASE 3]
• Sinopharm (China) [PHASE 3]
• Sinovac Biotech (China) [PHASE 3]
• Indian Council of Medical Research (India) & National Institute of Virology (India) & Bharat Biotech (India) [PHASE 3]
…..

Johnson & Johnson, AstraZeneca coronavirus vaccine trials set to resume: Investigators found the unexplained illnesses in both trials appeared unconnected to the vaccines (10/24/2020) | @washingtonpost
… In the Johnson & Johnson trial, which was paused on Oct. 12, a man who received a vaccination suffered a stroke that may have been triggered by an infection. To conclude it was not likely to be related to the shot, investigators probed not only the medical details of the event, but also examined a safety database of 100,000 people who have received vaccines that use the same underlying technology. …
… The company is testing the only vaccine that aims to protect people with a single shot; other prospective vaccines require a return visit and second shot three to four weeks after the first to trigger a protective immune response.
It was the second late-stage vaccine trial put on hold in recent weeks; the vaccine being developed by AstraZeneca and the University of Oxford was halted on Sept. 6 after a British participant developed a neurological problem. …
… Carlos del Rio, an infectious diseases physician at Emory University School of Medicine. “As long as the data and safety monitoring board has reviewed the data and says its OK to proceed, we proceed.”
… William Hartman, a principal investigator of the AstraZeneca trial at the University of Wisconsin Hospital and Clinics. “It is too soon to tell whether participant enthusiasm will approach what it was prior to the pause. …

Covid: More coronavirus vaccine trials in Wales ‘within weeks’ (24/10/2020) | @BBC

Rush for results could lead to inferior Covid vaccine, say scientists (25/10/2020) | @guardian

Dozens of COVID-19 vaccines are in development. Here are the ones to follow. : Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond. (10/13/2020) | @NatGeo
• Novavax (MD) NVX-CoV2373
• Johnson & Johnson (NJ) JNJ-78436735
• Moderna Therapeutics (MA) mRNA-1273
• Pfizer (NY) & BioNTech (Germany) BNT162b2
• University of Oxford (UK) & AstraZeneca (UK) ChAdOx1 nCoV-19
• Sinovac (China) & Butantan (Brazil) CoronaVac
• Sinopharm (China) & Wuhan Institute of Biological Products (China) None
• Murdoch Children’s Research Institute (Australia) & University of Melbourne (Australia) Bacillus Calmette-Guerin BRACE trial
• CanSino Biologics (China) Ad5-nCoV
• The Gamaleya National Center of Epidemiology and Microbiology (Russia) Sputnik V

Science and Technology 科学技術 Vol.7(#ArtificialIntelligence 人工知能 含む)/ #Coronavirus #コロナウイルス Vol.9

All the below links and tweets are in English.

取り急ぎ標記につき以下貼っておきます。

Science and Technology Vol.28 (incl Artificial Intelligence)
Science and Technology Vol.27
Science and Technology Vol.23
Science and Technology Vol.30 (incl #coronavirus)
Science and Technology Vol.29 (incl #coronavirus)
Science and Technology Vol.26 (#coronavirus)
Science and Technology Vol.25 (#coronavirus)
Science and Technology Vol.24 (#coronavirus)
Science and Technology Vol.22 (#coronavirus)

ツイッター検索で出て来た 人工知能 #ArtificialIntelligence の日本関連ツイート


https://twitter.com/DWIH_Tokyo/status/1062978942452215808


https://twitter.com/Ailish_Campbell/status/1272558313465618434

Cyber Security etc. サイバーセキュリティ等 Vol.5

All the below tweets are in English.

取り急ぎ標記につき以下貼っておきます。


https://twitter.com/coofish1/status/1235503278198124544


https://twitter.com/ChicagoCouncil/status/1220030256112971776


https://twitter.com/jennycohn1/status/1191825973265584129


https://twitter.com/DSMeu/status/1181978127557378055


https://twitter.com/FletcherSchool/status/1059634028524027904

#Coronavirus #コロナウイルス Vol.6 / Science and Technology 科学技術 Vol.6(Pharmaceutical products 医薬品 Vol.2:Drugs & Vaccines 治療薬及びワクチン)

取り急ぎ標記関連記事及びその一部抜粋を以下貼っておきます。
念のため申し上げますが、当方は(電子書籍出版時に製薬企業等につき調べましたのでほんの少しだけ予備知識があろうかとも思いますが)医薬品のいわゆる素人ですので、あくまでご参考までご覧ください。色々考える際に参考にはなるとも考えております。

Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19 (16/04/2020) | Praveen Duddu @ArenaClinical

Chloroquine approved for emergency use by US FDA
Favilavir, the first approved coronavirus drug in China

Pharmaceutical companies involved in developing coronavirus drugs/vaccines
[Novel coronavirus vaccines]
Fusogenix DNA vaccine by Entos Pharmaceuticals
… Fusogenix drug delivery platform is a proteo-lipid vehicle that introduces genetic payload directly into the cells. …
ChAdOx1 nCoV-19 by University of Oxford
…an adenovirus vaccine vector developed by the university’s Jenner Institute. …
Gimsilumab by Roivant Sciences
…a clinical-stage, human monoclonal antibody. The drug targets granulocyte-macrophage colony stimulating factor (GM-CSF), which is a pro-inflammatory cytokine found in high levels…
AdCOVID by Altimmune
…to develop a single dose intranasal vaccine for COVID-19 named AdCOVID. The company is currently carrying out immunogenicity studies after, which phase one clinical trial material will be developed. Altimmune and UAB will work with researchers to conduct preclinical animal studies and phase one clinical trial in the third quarter of 2020.
TJM2 by I-Mab Biopharma
…a neutralising antibody, as a treatment for cytokine storm in patients suffering from a severe case of coronavirus infection. The drug targets the human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is responsible for acute and chronic inflammation.
Coronavirus vaccine by Medicago
…after having produced Virus-Like Particles (VLP)… …a collaboration with Laval University’s Infectious Disease Research Centre…
AT-100 by Airway Therapeutics
…novel human recombinant protein named AT-100 (rhSP-D)… AT-100 has shown efficacy in preclinical studies in reducing inflammation and infection in the lungs, while also generating an immune response against various respiratory diseases.
TZLS-501 by Tiziana Life Sciences
…monoclonal antibody named TZLS-501… …a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6. …reducing chronic lung inflammation.
OYA1 by OyaGen
BPI-002 by BeyondSpring
…a small molecule agent indicated for treating various infections… …to activate CD4+ helper T cells and CD8+ cytotoxic T cells and generating an immune response in the body. If combined with another COVID-19 vaccine, the drug has the ability to generate long-term protection against viral infections. …
Altimmune’s intranasal coronavirus vaccine
…being developed based on a vaccine technology platform that is similar to NasoVAX, an influenza vaccine developed by Altimmune.
INO-4800 by Inovio Pharmaceuticals and Beijing Advaccine Biotechnology
NP-120 (Ifenprodil) by Algernon Pharmaceuticals
…an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist sold under the brand name Cerocal. …
APN01 by University of British Columbia and APEIRON Biologics
…ACE2 protein was the main receptor for the SARS virus. …
mRNA-1273 vaccine by Moderna and Vaccine Research Center
…targets the Spike (S) protein… …shipped to NIAID for phase one human clinical trial. …
Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine by MIGAL Research Institute
…efficacy in pre-clinical trials conducted by the Volcani Institute. …in the oral form. …
TNX-1800 by Tonix Pharmaceuticals
…a modified horsepox virus developed using Tonix’s proprietary horsepox vaccine platform. … Southern Research will be responsible for evaluating the efficacy of the vaccine, under the partnership.
Brilacidin by Innovation Pharmaceuticals
…a defensin mimetic drug candidate, as a potential treatment… …has shown antibacterial, anti-inflammatory and immunomodulatory properties in several clinical trials. …already investigating the drug for inflammatory bowel disease and oral mucositis in cancer patients. …has signed two material transfer agreements with a university in the US and 12 biocontainment labs in the US for evaluation…
Recombinant subunit vaccine by Clover Biopharmaceuticals
…a recombinant subunit vaccine using its patented Trimer-Tag© technology. …binding with the host cell and causing a viral infection. …successfully produced the subunit vaccine in a mammalian cell-culture based expression system… …antigen-specific antibody in the serum of fully recovered patients who were previously infected by the virus. …equipped with in-house cGMP biomanufacturing capabilities…
Vaxart’s coronavirus vaccine
…in tablet formulation using its proprietary oral vaccine platform, VAAST. …for mucosal and systemic immune responses.
CytoDyn-leronlimab
…(PRO 140), a CCR5 antagonist, as a potential coronavirus drug. …being investigated in phase two clinical trials as a treatment for HIV and has been awarded fast-track approval status…
Linear DNA Vaccine by Applied DNA Sciences and Takis Biotech
…will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology… …high purity, increased production speed, and absence of antibiotics and bacterial contaminants. …can be effective without being inserted into the patient’s genome. …based on the entire spike gene of the coronavirus, while…based on the antigenic portions of the protein.
BXT-25 by BIOXYTRAN to treat late-stage acute respiratory distress syndrome (ARDS)
…in late-stage patients infected with the coronavirus. The diffusion of oxygen to the blood is comprised in patients suffering from ARDS leading to fluid build-up in the lungs. …designed to be 5,000 times smaller than blood cells and efficiently transport oxygen through the body for a period of nine hours before being processed by the liver. The drug can help in supplying oxygen to the vital organs and enable the patient to recover and survive.
Novavax’s MERS coronavirus vaccine candidate
…designed to primarily bind to the major surface S-protein and developed using the company’s recombinant nanoparticle vaccine technology. Tested along with the Novavax’s proprietary adjuvant Matrix-M™, it inhibited infection by inducing immune responses in the laboratory studies.
Inovio Pharma’s INO-4700
…being developed by Inovio in partnership with GeneOne Life Science. It is delivered as vaccine intramuscularly, using the Cellectra® delivery device.

[Coronavirus drugs]
Remdesivir (GS-5734) by Gilead Sciences
Actemra by Roche to treat coronavirus-related complications
China approved the use of Roche’s Actemra for the treatment of severe complications… …the ability to prevent cytokine storms or overreaction of the immune system, which is considered as the main reason behind organ failure…
Biocryst Pharma’s Galidesivir, a potential antiviral for coronavirus treatment
…(BCX4430) has shown broad-spectrum activity against a wide range of pathogens… …a nucleoside RNA polymerase inhibitor that disrupts the process of viral replication. …has already shown survival benefits in patients against deadly viruses such as Ebola, Zika, Marburg, and Yellow fever. …to combat multiple potential viral threats including coronaviruses, flaviviruses filoviruses, paramyxoviruses, togaviruses, bunyaviruses, and arenaviruses.
Regeneron’s REGN3048-3051 and Kevzara
…the combination of neutralising monoclonal antibodies REGN3048 and REGN3051… Both the antibodies bind to S-protein of MERS coronavirus. …in the mouse model of MERS resulted in the high-level neutralisation of the MERS coronavirus in circulating blood with reduced viral loads in the lungs. … Kevzara is approved for the treatment of rheumatoid arthritis and is known to block the interleukin-6 (IL-6) pathway, which causes an overactive inflammatory response…
SNG001 by Synairgen Research
…an inhaled drug, is planned to be tested by the University of Southampton to treat asthma, chronic obstructive pulmonary disease and lower respiratory tract illnesses… …a formulation of naturally occurring Interferon-β, which is administered through a nebuliser and is delivered directly to the lungs to reduce the severity…
AmnioBoost by Lattice Biologics
…exploring the efficacy of its amniotic fluid concentrate, AmnioBoost, in treating acute respiratory distress syndrome (ARDS)… …for chronic adult inflammatory conditions such as osteoarthritis. …reduces the production of pro-inflammatory cytokines while boosting the production of anti-inflammatory cytokines.

Other companies developing coronavirus vaccines/drugs
Enanta Pharmaceuticals
…plans to develop antiviral drug candidates…
Predictive Oncology
…an AI Platform for the discovery and development of vaccines… …has signed an agreement with InventaBioTech to acquire Soluble Therapeutics, which provides it with access to the HSCTM Technology.
Emergent BioSolutions
…developing two plasma-derived product candidates or hyperimmunes using its hyperimmune platforms… …including vaccines for smallpox, botulism, and anthrax. … The hyperimmunes are polyclonal antibodies derived from plasma, which are capable of generating an immune response and protecting against infection. …with a severe case…
Integral Molecular
…has launched a vaccine programme using its two technology platforms including Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array. …isolate the cellular receptors that enable the virus to spread quickly. …while the Membrane Proteome Array technology is capable of identifying the receptors through which viruses infect cells.
CEL-SCI
…using its proprietary LEAPS peptide technology, which utilises conserved areas of the coronavirus proteins to generate T-cell responses and reduce viral load. …to develop immunotherapeutic peptides with both antiviral and anti-inflammatory properties. …in reducing tissue damage from inflammation caused due to lung infection, which is a major cause of mortality in elderly patients.
AJ Vaccines
…will use the latest technology to develop antigens that can mimic the native structures of the virus. …
Takeda Pharmaceutical Company
… The anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) therapy will be designed to treat high-risk patients. The H-IG therapy includes concentrated pathogen-specific antibodies derived from plasma of recovered patients. …
Heat Biologics
…using its proprietary gp96 vaccine platform. …reprogramming live cells to produce antigens that can bind to the gp96 protein and generate an immune response against those antigens.
Pfizer
…antiviral compounds…
Mateon Therapeutics
…an antiviral response programme to develop coronavirus treatments using its therapeutic and artificial intelligence (AI) platforms. …
Hong Kong University of Science and Technology
…have identified B-cell and T-cell epitopes, which are capable of generating an immune response against the SARS virus and a similar response…
Vaccine by Generex
…following a contract from a Chinese consortium comprising of China Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development. The company will utilise its Ii-Key immune system activation technology to produce a COVID-19 peptide for human clinical trials.
Coronavirus drugs by Columbia University
Vaccine by Tulane University
Coronavirus vaccine by ImmunoPrecise Antibodies
…will use its B Cell Select™ and DeepDisplay™ discovery platforms to therapeutic compounds… …will be using the PolyTope mAb TherapyTM and EVQLV’s artificial intelligence platforms develop a COVID-19 therapy.
Serum Institute of India
…collaborating with Codagenix, a US-based biopharmaceutical company, to develop a cure for coronavirus using a vaccine strain similar to the original virus. …
Southwest Research Institute
…virtual screening called Rhodium…
Zydus Cadila
…two novel approaches. The first approach includes the development of a DNA vaccine against the viral membrane protein of the virus, while a live attenuated recombinant measles virus (rMV) vectored vaccine will be developed in the second approach. The rMV-based vaccine works by inducing specific neutralising antibodies…
NanoViricides
…developing a treatment for nCoV-2019 using its nanoviricide® technology. …used to develop ligands that can bind to the virus in the same way as a cognate receptor and attack various points of the virus.
Vir Biotechnology
…a clinical-stage immunology company… has identified two monoclonal antibodies that can bind to the virus… The antibodies target the spike (S) protein of the virus by entering through the cellular receptor ACE2. …a partnership with WuXi Biologics… …also partnered with Alnylam Pharmaceuticals to identify siRNA candidates… …another partnership with Biogen for cell line and process development and manufacturing…
HIV drugs for coronavirus treatment
Abbvie’s HIV protease inhibitor, lopinavir is being studied along with ritonavir for the treatment of MERS and SARS coronaviruses. …HIV infection under the trade name Kaletra®. … Lopinavir is believed to act on the intracellular processes of coronavirus replication and demonstrated reduced mortality in the non-human primates (NHP) model of the MERS. Lopinavir/ritonavir in combination with ribavirin showed reduced fatality rate and milder disease course during an open clinical trial in patients in the 2003 SARS outbreak. Cipla is also reportedly planning to repurpose its HIV drug LOPIMUNE, which is a combination of protease inhibitors Lopinavir and Ritonavir…
Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, donated its PREZCOBIX® HIV medication (darunavir/cobicistat)… Darunavir is a protease inhibitor… …as potentially having antiviral activity… …has no in vitro or clinical data… …has partnered with the Biomedical Advanced Research and Development Authority (BARDA)…

#Coronavirus #コロナウイルス Vol.5 / Science and Technology 科学技術 Vol.5(Pharmaceutical products 医薬品 Vol.1:Drugs & Vaccines 治療薬及びワクチン)

ご参考まで標記関連記事及び一部抜粋を以下貼っておきます。

Reasons for hope: The drugs, tests and tactics that may conquer coronavirus(04/17/2020) | Christine Soares @reuters,@stltoday

DRUGS
Remdesivir (Gilead Sciences)
Antiviral drug, originally developed to combat RNA viruses including respiratory syncytial virus. …antivirals work best when patients are healthier…
Hydroxychloroquine and chloroquine
Malaria drug also believed to have antiviral activity. Blocked SARS-CoV-2 entry into cells in an in-vitro experiment. …
Actemra or tocilizumab (Roche)
Monoclonal antibody approved for rheumatoid arthritis and also for treating the “cytokine storm” immune overresponse in cancer patients. …
Kevzara or sarilumab (Sanofi, Regeneron Pharmaceuticals)
Monoclonal antibody approved for inflammatory arthritis, and in trials targeting the “cytokine storm” immune response in severely ill COVID-19 patients. …
Jakavi or ruxolitinib (Novartis, Incyte)
Developed to treat inflammatory and autoimmune diseases, and in late-stage development as a cream for atopic dermatitis. …
Kaletra or lopinavir-ritonavir (Abbvie)
Antiviral combination used to treat and prevent HIV infections. …
(rhACE2) APN01 (Apeiron Biologics)
A recombinant human angiotensin converting enzyme 2 (rhACE2) under Phase-2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). …
Camostat Mesylate (University of Aarhus, Denmark)
Protease inhibitor licensed in Japan and South Korea to treat chronic pancreatitis. In vitro experiments found it blocks a mechanism SARS-Cov-2 uses to enter human cells. … The University of Tokyo also announced plans for a trial of camostat mesylate and a related drug, nafamostat mesylate, starting as early as April 2020.
IFX-1 (InflaRx)
Monoclonal antibody targeting complement activation product C5a. Designed to block a mechanism of inflammation…
Aspirin, clopidogrel, rivaroxaban, atorvastatin, omeprazole (Imperial College, London)
Trial of cardioprotective drugs to prevent direct damage to the heart muscle that appears to drive the severity of COVID-19…

VACCINES
MRNA 1273 (Moderna/NIAID)
RNA vaccine made with messenger-RNA (mRNA) encoding the spike protein of SARS-CoV-2 encapsulated in a lipid nanoparticle. …
NVX-COV2373 (Novavax)
…enhance immune responses. …
Lentiviral minigene vaccines (LV-SMENP) (Shenzhen Geno-Immune Medical Institute)
Engineered minigenes encoding viral antigens; lentiviral vector designed to infect dendritic and T cells to induce immunity. …
BCG tuberculosis vaccine (Murdoch Children’s Research Institute; UMC Utrecht)
Bacillus Calmette-Guérin tuberculosis vaccine that induces a broad innate immune-system response, which has been shown to protect against infection or severe illness with other respiratory pathogens. …
INO-4800 (Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations)
DNA plasmid vaccine delivered into the skin via a patch-style electroporation device. …
AD5-NCOV (Cansino Biological Inc. / Beijing Institute of Biotechnology)
Non-replicating viral vector. …
CHADOX1 (University of Oxford)
Non-replicating chimpanzee adenovirus vector. …

#Coronavirus #コロナウイルス Vol.3 / Science and Technology 科学技術 Vol.3

What does 5G have to do with coronavirus? Where did it come from? Your questions answered (09/04/2020) | @DWNews

コロナウイルス関連説明が分かり易いので、下記抜粋をご紹介します。

Where did SARS-CoV-2 come from?
Scientific consensus agrees that the novel coronavirus is natural — it’s a zoonotic disease, meaning it was transmitted from animals to humans. It’s widely thought that the virus originated in bats, before possibly passing through another mammal that infected a human.
In early February, Nature published a study showing that the novel coronavirus is 96% identical at the whole-genome level to a bat coronavirus.
Another study found that pangolins — a scaly anteater that is heavily trafficked in parts of Asia and Africa — carry coronaviruses that are very similar to SARS-CoV-2. …

Will I die of COVID-19?
This question can’t be answered with a simple “yes” or “no,” just like death from the flu or a car accident can’t be predicted with certainty. We can only speak of probabilities. And even that is not so easy in the case of COVID-19, which is why we have prepared a detailed breakdown of the statistics here …
… the virus’ casualty rate is between 0.5 to 2%, i.e. one or two people die out of every 100 people who are infected.

How long can the virus survive in the air or on surfaces?
… But the good news is that the virus needs a live host to survive. Without a live host, the virus eventually dies out because it can’t copy itself. So while it may survive on some surfaces for hours and even days, over time it becomes less infectious because, without being able to replicate, the virus breaks down over time.
… temperature changes and sunlight — that could affect the stability of the virus.

Why isn’t there a vaccine yet?
It normally takes years to develop an effective and safe vaccine.
… there are at least 47 ongoing projects globally focussing on the development of a coronavirus vaccine. …
… Scientists at the DZIF use pre-existing “building blocks” from previously formulated vaccines to work towards the development of a coronavirus vaccine. Although the scientists are working under high pressure, it’s not possible for a vaccine to be launched on the market this year. The clinical studies, which are crucial for approval, take time.
Parallel to the development of the vaccine, some researchers are working on developing a “passive immunization” with antibodies derived from blood serum. These come from people who have survived a SARS-CoV-2 infection and therefore have antibodies in their blood that can fight the virus.
It’s called passive immunization, because the recipient body hasn’t actively produced any antibodies itself. And as a result, the antibodies it “borrows” will provide protection or help to fight an infection, but only for a short period of time. Only a traditional vaccine will provide long term protection from coronavirus. …

Pinned tweets, etc. 固定ツイート等

アイルランドの政治・行政・企業・地方・大学: 英文脚注15000以上―アイルランド・米国・英国・欧州・日本企業情報を含む Kindle版 中港拓 (著)

#FoodexJapan2019 non-Japanese companies #フーデックスジャパン2019 外国企業(於:幕張メッセ Makuhari Messe)
https://twitter.com/WSjp_insight/status/1115147825342345217
U.K. イギリス Vol.18(北アイルランド Northern Ireland)
U.K. イギリス Vol.19(スコットランド Scotland)
U.K. イギリス Vol.20(ウェールズ Wales)

U.K. イギリス Vol.16(Brexit Vol.13:報道等において正面から触れられていないブレグジット三点 3 points concerning Brexit which have not been confronted in the media etc.)
U.K. Vol.17(Brexit Vol.14: 3 points concerning Brexit which have not been confronted in the media etc. – especially outside the United Kingdom and the Republic of Ireland)


EU-Japan Economic Partnership Agreement 日EU経済連携協定(EUJEPA)Vol.2


EUJEPA Vol.3
TPP Vol.4
TPP Vol.5
TPP Vol.6


ツイート:サイバーセキュリティ


SNSは複雑単純あるにしてもどれでも使い続けないと正直よく分からないものであると認識していますが、当方が唯一使い続けているツイッターの良さは
1.設定が全体に自由かつ簡単であり、また、それゆえもあり拡散力に優れてもいる
2.そのため、難しい話を内容とするディスカッション、コンテンツマーケティング、キュレーションに適している。
こういう良さを備えるSNSは、今後も出て来ないように感じます。
そもそも、情報が有り過ぎて困る今の時代には、ある意味キュレーション無くして物事の正確な理解はできません。
この意味では、キュレーション等のためのツイッターも、その存在無くして今の時代を語れないとも言い得ます。
フォロワー数やリツイート数・ライク数よりも、コンテンツの質が重要とも言えます。

https://twitter.com/WSjp_insight/status/1106487409204555776
Honestly, we have understood that it is difficult to understand how to use social network services, if we don’t keep using some specific ones, regardless of being complicated or simple. The strengths of Twitter, which we have kept using as our single tool, would be:
1. in general, we can set it freely and easily, and so forth as well, it is good at spreading stories on the Internet;
2. therefore it is suitable to discussions, content marketing, curation, etc. on difficult topics or contents.
It seems that there will not be such strong services other than Twitter.
Today, when there is too much information, in a sense, it is impossible to accurately understand news without curation.
In this sense, it would be impossible to talk about current era without presense of Twitter, which is suitable to curation, etc.
We can say that the quality of contents is far more important than the numbers of followers, retweets, likes, etc.

ご参考:
1.(無料で使用しているので思うような表示にはなっておりませんが)一応、https://9223.teacup.com/ireland_corps/bbs という(概ね日本語 Mostly in Japanese の)デジタルサイネージ digital signage があります。アイルランド関連・電子書籍関連に可能な限り絞って貼って行こうと考えています。
2.https://www.goodreads.com/world_solutions (in English)
これは引き続き、若干趣味的に試行錯誤の最中です。フィクション作品愛好者が圧倒的に多い、更新後の内容が表れるのが半日くらい後である、などの特徴があると言えそうです。
3.2019年4月16日、書籍Facebookページを公開停止といたしました。今までご覧頂いた等の方々、誠にありがとうございました。引き続き、本ウェブサイトやツイッター等をご覧頂ければ幸甚です。
On April 16, 2019, we stopped publishing the eBook-related Facebook page. Thank you so much for having visited that page, etc. We would be very pleased if you continue visiting this website, Twitter accounts, the Teacup digital signage, etc.

2018 FIFA World Cup Russia ロシアW杯 Vol.5

All the below tweets are in English.

さて、日本時間で海の日(今週月曜日)に、フランス優勝という結果で、サッカーのワールドカップが終わりました。
ツイートを見るだけでも、時代が進み、色々な関連事項がある旨を感じた次第です。取り急ぎ、標記関連ツイートを以下貼っておきます。


https://twitter.com/RedDevilTimes/status/1014287508920766465


https://twitter.com/DatavisDaily/status/1009439509065461761


https://twitter.com/betonchart/status/1017107515102855168


https://twitter.com/WilliamHill/status/1018519061385408512
https://twitter.com/WilliamHill/status/1018167680338137088

https://twitter.com/WSjp_insight/status/1013461098979135488

2018 FIFA World Cup Russia ロシアW杯 Vol.4(Winner 優勝/Top scorer 得点王 など)

All the below links are in English.

日本代表チームについて一国民として今も色々な想いや分析はありますが、可能な限り客観的で偏り無く汎用性ある情報で満たすという当サイト・キュレーションの方針に則りここでは展開いたしません。
選手、監督コーチほか、様々な方々、お疲れさまでした。
一個人として、本当に可能な範囲で応援しましたし、本当に精神面分析面で勉強になりました。

15日まで続くW杯で今後気になるのは、準々決勝以上の好ゲーム、得点王 * 等の活躍選手でしょうか。
ドイツもスペインもアルゼンチンもポルトガルも既に敗退しており、Cロナウドやメッシも既に居らず、毎回同様混沌としていると言えます。
あくまで復習用という感じの情報でしかありませんが、以下、今日現在ネットで無理なく見つかる関連の記事を取り急ぎ貼っておきます。

World Cup 2018 last 16: match dates, teams and predictions for remaining quarter-finalists (03/07/2018) | @Telegraph

2018 World Cup predictions: Winners, losers, top-scorers and players to watch (06/06/2018 updated) | The National

Who will be top scorer at the World Cup 2018? (w Podcast; 04/18/2018) | @ManuelVeth Futbolgrad
Selling the People’s Game: Football’s transition from Communism to Capitalism in the Soviet Union and its Successor State (PDF; 2016) | Karl Manuel Veth @ King’s College London 投稿翌日追記.何故か昨日より少し繋がりにくくなっています?

Here are the top scorers of Fifa World Cup 2018 for Golden Boot standings (07/03/2018) | Business Standard

Golden Boot (will be updated throughout the tournament) | Frank Hulley-Jones and Sean Clarke @guardian
Your complete guide to all 736 players at the 2018 World Cup (05/06/2018) | @guardian

* 投稿翌日追加. 欧州時間7月3日に、得点王予想記事が増えてきました。実際に決まるまでに、ストライカーの段違いの凄みを感じさせて欲しい、と個人的には思います。
World Cup – Top Goalscorer Betting Odds | oddschecker
KANE NOW ODDS-ON FAVORITE TO WIN GOLDEN BOOT (07/03/2018) | Rob Trites
Golden Boot betting guide: World Cup 2018 top goalscorer odds (07/03/2018) | Ben Green
World Cup 2018 odds for outright winner, top scorer and finalists as favourites and predictions revealed for Russia (07/02/2018)
World Cup golden boot 2018: Harry Kane, Romelu Lukaku or Kylian Mbappe – who will win race to be top goal scorer? (03/07/2018) | @Independent

投稿翌々日再追加. Predictions Vol.2 (FIFA World Cup 2018) に本投稿URLの2つが含まれています。
個人的には、統計学を妄信することは決してありませんが、適宜把握しておくことも必要であるとも認識しています。

2018 FIFA World Cup Russia ロシアW杯 Vol.1(Los cracks del fútbol サッカーのレジェンド)

ワールドカップ開催中、日本代表3戦目勝利・決勝T進出を祈念して、珍しく投稿2回連続でbreakです。
名選手(crack)5人の古い映像YouTubeに遭遇しましたので、例として貼っておきます。

Alfredo Stéfano Di Stéfano Laulhé 

Pelé(Edson Arantes do Nascimento) 

Johan Cruyff 

Franz Anton Beckenbauer 

Diego Armando Maradona Franco